Cargando…

Immune characterization of metastatic colorectal cancer patients post reovirus administration

BACKGROUND: KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination with chemotherapy is examined in a phase 1 study o...

Descripción completa

Detalles Bibliográficos
Autores principales: Parakrama, Ruwan, Fogel, Elisha, Chandy, Carol, Augustine, Titto, Coffey, Matt, Tesfa, Lydia, Goel, Sanjay, Maitra, Radhashree
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301987/
https://www.ncbi.nlm.nih.gov/pubmed/32552875
http://dx.doi.org/10.1186/s12885-020-07038-2
_version_ 1783547779845455872
author Parakrama, Ruwan
Fogel, Elisha
Chandy, Carol
Augustine, Titto
Coffey, Matt
Tesfa, Lydia
Goel, Sanjay
Maitra, Radhashree
author_facet Parakrama, Ruwan
Fogel, Elisha
Chandy, Carol
Augustine, Titto
Coffey, Matt
Tesfa, Lydia
Goel, Sanjay
Maitra, Radhashree
author_sort Parakrama, Ruwan
collection PubMed
description BACKGROUND: KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination with chemotherapy is examined in a phase 1 study of metastatic CRC. This study evaluates the nature of immune response by determining the cytokine expression pattern in peripheral circulation along with the distribution of antigen presenting cells (APCs) and activated T lymphocytes. Further the study evaluates the alterations in exosomal and cellular microRNA levels along with the effect of reovirus on leukocyte transcriptome. METHODS: Reovirus was administered as a 60-min intravenous infusion for 5 consecutive days every 28 days, at a tissue culture infective dose (TCID(50)) of 3 × 10(10). Peripheral blood mononuclear cells (PBMC) were isolated from whole blood prior to reovirus administration and post-reovirus on days 2, 8, and 15. The expression profile of 25 cytokines in plasma was assessed (post PBMC isolation) on an EMD Millipore multiplex Luminex platform. Exosome and cellular levels of miR-29a-3p was determined in pre and post reovirus treated samples. Peripheral blood mononuclear cells were stained with fluorophore labelled antibodies against CD4, CD8, CD56, CD70, and CD123, fixed and evaluated by flow cytometry. The expression of granzyme B was determined on core biopsy of one patient. Finally, Clariom D Assay was used to determine the expression of 847 immune-related genes when compared to pre reovirus treatment by RNA sequencing analysis. A change was considered if the expression level either doubled or halved and the significance was determined at a p value of 0.001. RESULTS: Cytokine assay indicated upregulation at day 8 for IL-12p40 (2.95; p = 0.05); day 15 for GM-CSF (3.56; p = 0.009), IFN-y (1.86; p = 0.0004) and IL-12p70 (2.42; p = 0.02). An overall reduction in IL-8, VEGF and RANTES/CCL5 was observed over the 15-day period. Statistically significant reductions were observed at Day 15 for IL-8 (0.457-fold, 53.3% reduction; p = 0.03) and RANTES/CC5 (0.524-fold, 47.6% reduction; p = 0.003). An overall increase in IL-6 was observed, with statistical significance at day 8 (1.98- fold; 98% increase, p = 0.00007). APCs were stimulated within 48 h and activated (CD8(+) CD70(+)) T cells within 168 h as determine by flow cytometry. Sustained reductions in exosomal and cellular levels of miR-29a-3p (a microRNA upregulated in CRC and associated with decreased expression of the tumor suppressor WWOX gene) was documented. Reovirus administration further resulted in increases in KRAS (33x), IFNAR1 (20x), STAT3(5x), and TAP1 (4x) genes after 2 days; FGCR2A (23x) and CD244 (3x) after 8 days; KLRD1 (14x), TAP1 (2x) and CD244(2x) after 15 days. Reductions (> 0.5x) were observed in VEGFA (2x) after 2 days; CXCR2 (2x), ITGAM (3x) after 15 days. CONCLUSIONS: Reovirus has profound immunomodulatory properties that span the genomic, protein and immune cell distribution levels. This is the first study with reovirus in cancer patients that demonstrates these multi- layered effects, demonstrating how reovirus can function as an immune stimulant (augmenting the efficacy of immuno-chemo-therapeutic drugs), and an oncolytic agent. Reovirus thus functions bimodally as an oncolytic agent causing lysis of tumor cells, and facilitator of immune-mediated recognition and destruction of tumor cells. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-7301987
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73019872020-06-19 Immune characterization of metastatic colorectal cancer patients post reovirus administration Parakrama, Ruwan Fogel, Elisha Chandy, Carol Augustine, Titto Coffey, Matt Tesfa, Lydia Goel, Sanjay Maitra, Radhashree BMC Cancer Research Article BACKGROUND: KRAS mutations are prevalent in 40–45% of patients with colorectal cancer (CRC) and targeting this gene has remained elusive. Viruses are well known immune sensitizing agents. The therapeutic efficacy of oncolytic reovirus in combination with chemotherapy is examined in a phase 1 study of metastatic CRC. This study evaluates the nature of immune response by determining the cytokine expression pattern in peripheral circulation along with the distribution of antigen presenting cells (APCs) and activated T lymphocytes. Further the study evaluates the alterations in exosomal and cellular microRNA levels along with the effect of reovirus on leukocyte transcriptome. METHODS: Reovirus was administered as a 60-min intravenous infusion for 5 consecutive days every 28 days, at a tissue culture infective dose (TCID(50)) of 3 × 10(10). Peripheral blood mononuclear cells (PBMC) were isolated from whole blood prior to reovirus administration and post-reovirus on days 2, 8, and 15. The expression profile of 25 cytokines in plasma was assessed (post PBMC isolation) on an EMD Millipore multiplex Luminex platform. Exosome and cellular levels of miR-29a-3p was determined in pre and post reovirus treated samples. Peripheral blood mononuclear cells were stained with fluorophore labelled antibodies against CD4, CD8, CD56, CD70, and CD123, fixed and evaluated by flow cytometry. The expression of granzyme B was determined on core biopsy of one patient. Finally, Clariom D Assay was used to determine the expression of 847 immune-related genes when compared to pre reovirus treatment by RNA sequencing analysis. A change was considered if the expression level either doubled or halved and the significance was determined at a p value of 0.001. RESULTS: Cytokine assay indicated upregulation at day 8 for IL-12p40 (2.95; p = 0.05); day 15 for GM-CSF (3.56; p = 0.009), IFN-y (1.86; p = 0.0004) and IL-12p70 (2.42; p = 0.02). An overall reduction in IL-8, VEGF and RANTES/CCL5 was observed over the 15-day period. Statistically significant reductions were observed at Day 15 for IL-8 (0.457-fold, 53.3% reduction; p = 0.03) and RANTES/CC5 (0.524-fold, 47.6% reduction; p = 0.003). An overall increase in IL-6 was observed, with statistical significance at day 8 (1.98- fold; 98% increase, p = 0.00007). APCs were stimulated within 48 h and activated (CD8(+) CD70(+)) T cells within 168 h as determine by flow cytometry. Sustained reductions in exosomal and cellular levels of miR-29a-3p (a microRNA upregulated in CRC and associated with decreased expression of the tumor suppressor WWOX gene) was documented. Reovirus administration further resulted in increases in KRAS (33x), IFNAR1 (20x), STAT3(5x), and TAP1 (4x) genes after 2 days; FGCR2A (23x) and CD244 (3x) after 8 days; KLRD1 (14x), TAP1 (2x) and CD244(2x) after 15 days. Reductions (> 0.5x) were observed in VEGFA (2x) after 2 days; CXCR2 (2x), ITGAM (3x) after 15 days. CONCLUSIONS: Reovirus has profound immunomodulatory properties that span the genomic, protein and immune cell distribution levels. This is the first study with reovirus in cancer patients that demonstrates these multi- layered effects, demonstrating how reovirus can function as an immune stimulant (augmenting the efficacy of immuno-chemo-therapeutic drugs), and an oncolytic agent. Reovirus thus functions bimodally as an oncolytic agent causing lysis of tumor cells, and facilitator of immune-mediated recognition and destruction of tumor cells. GRAPHICAL ABSTRACT: [Image: see text] BioMed Central 2020-06-18 /pmc/articles/PMC7301987/ /pubmed/32552875 http://dx.doi.org/10.1186/s12885-020-07038-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Parakrama, Ruwan
Fogel, Elisha
Chandy, Carol
Augustine, Titto
Coffey, Matt
Tesfa, Lydia
Goel, Sanjay
Maitra, Radhashree
Immune characterization of metastatic colorectal cancer patients post reovirus administration
title Immune characterization of metastatic colorectal cancer patients post reovirus administration
title_full Immune characterization of metastatic colorectal cancer patients post reovirus administration
title_fullStr Immune characterization of metastatic colorectal cancer patients post reovirus administration
title_full_unstemmed Immune characterization of metastatic colorectal cancer patients post reovirus administration
title_short Immune characterization of metastatic colorectal cancer patients post reovirus administration
title_sort immune characterization of metastatic colorectal cancer patients post reovirus administration
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7301987/
https://www.ncbi.nlm.nih.gov/pubmed/32552875
http://dx.doi.org/10.1186/s12885-020-07038-2
work_keys_str_mv AT parakramaruwan immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration
AT fogelelisha immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration
AT chandycarol immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration
AT augustinetitto immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration
AT coffeymatt immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration
AT tesfalydia immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration
AT goelsanjay immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration
AT maitraradhashree immunecharacterizationofmetastaticcolorectalcancerpatientspostreovirusadministration